12 Health Care Stocks Moving In Monday’s Intraday Session
Gainers Bionomics (NASDAQ:BNOX) stock moved upwards by 32.7% to $2.03 during Monday’s regular session. Trading volume for Bionomics’s…
Analyst Ratings for SAB Biotherapeutics
Within the last quarter, SAB Biotherapeutics (NASDAQ:SABS) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
SAB Biotherapeutics Q2 EPS $(0.14) Down From $(0.11) YoY
Q2 2023 Financial Results
Financial Guidance: Based on its current operating plans, SAB reaffirms that it expects its existing business plan, cash and cash equivalents, and anticipated cash flows will be sufficient to
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers NuCana (NASDAQ:NCNA) stock rose 17.3% to $0.84 during Friday’s after-market session. This security traded at a volume…
EXCLUSIVE: SAB Biotherapeutics Says Diabetes Immunotherapy Shows Therapeutic Effect In Toxicology Study
SAB Biotherapeutics Inc (NASDAQ: SABS) announced the presentation of safety and pharmacologic data from a GLP toxicology study for SAB-142, a fully human immunotherapeutic being developed for delaying the onset and progression of Type 1 Diabetes.
SAB Biotherapeutics To Present Novel Human IgG Platform With Data And Breakthrough Therapy And Fast-Track Designations For Influenza Treatment At BIO 2023 International Convention
SAB Biotherapeutics (NASDAQ:SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin (hIgG)
SAB Biotherapeutics: Q1 Earnings Insights
SAB Biotherapeutics (NASDAQ:SABS) reported its Q1 earnings results on Tuesday, May 16, 2023 at 08:30 AM. Here’s what…
12 Health Care Stocks Moving In Thursday’s Pre-Market Session
Gainers Soligenix (NASDAQ:SNGX) shares moved upwards by 142.9% to $3.45 during Thursday’s pre-market session. The market value of…
EXCLUSIVE: SAB Biotherapeutics’ Influenza Immunotherapy Shows Safety, Efficacy In Early-Stage Trials
SAB Biotherapeutics Inc (NASDAQ: SABS) has announced the presentation of safety and efficacy data from Phase 1 and 2a trials of its influenza immunotherapy, SAB-176.
EXCLUSIVE: SAB Biotherapeutics Releases Topline Data From Discontinued COVID Antibody Trial
SAB Biotherapeutics Inc (NASDAQ: SABS) has revealed topline results from the Phase 3 National Institutes of Health's (NIH) ACTIV-2 trial that assessed SAB-185 in non-hospitalized COVID-19 patients at high risk for severe outcomes.